COMPARISON OF EUROPEAN AND USA GUIDELINES FOR PREVENTION OF CORONARY-HEART-DISEASE

被引:10
|
作者
STEIN, Y
机构
[1] Lipid Research Laboratory, Department of Medicine, Hadassah University Hospital, Jerusalem
关键词
HYPERLIPIDEMIA; ATHEROSCLEROSIS; HDL; LDL; RISK FACTORS;
D O I
10.1016/0021-9150(94)05376-T
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This paper deals with the comparison of European and American guidelines for prevention of CHD, screening and management of hyperlipidemia. The revised EAS guidelines consist of 4 chapters: the scientific basis of CHD prevention; strategies for prevention of CHD; setting up a primary care system for CHD prevention, and the fourth focuses on clinical management with healthy diet, lifestyle and drug treatment of risk factors for CHD. The EAS guidelines emphasize that therapeutic decisions are based on the assessment of the global risk of CHD. In both EAS and American guidelines, optimal total plasma cholesterol and triglyceride target values recommended are < 200 mg/dl for both parameters. Both guidelines state that the initial approach to the treatment of hyperlipidemia should involve diet, increased physical activity, and weight reduction. If target levels are not achieved, the physician should determine whether drug therapy is appropriate. Conservative measures (diet and exercise) are recommended in particular for premenopausal women, elderly subjects and adolescents. There is complete agreement on the importance of secondary prevention of CHD.
引用
收藏
页码:S41 / S44
页数:4
相关论文
共 50 条
  • [21] Comparing the New European Cardiovascular Disease Prevention Guideline With Prior American Heart Association Guidelines: An Editorial Review
    Ton, Van-Khue
    Martin, Seth S.
    Blumenthal, Roger S.
    Blaha, Michael J.
    CLINICAL CARDIOLOGY, 2013, 36 (05) : E1 - E6
  • [22] Anacetrapib: potential for the prevention and treatment of coronary heart disease
    Steen, Dylan L.
    Khera, Amit V.
    Cannon, Christopher P.
    RESEARCH REPORTS IN CLINICAL CARDIOLOGY, 2013, 4 : 39 - 53
  • [23] The role of lipid metabolism in the prevention of coronary heart disease
    Mathes, P
    Thiery, J
    ZEITSCHRIFT FUR KARDIOLOGIE, 2005, 94 : 43 - 55
  • [24] Effectiveness of nonpharmacological secondary prevention of coronary heart disease
    Mueller-Riemenschneider, Falk
    Meinhard, Charlotte
    Damm, Kathrin
    Vauth, Christoph
    Bockelbrink, Angelina
    Greiner, Wolfgang
    Willich, Stefan N.
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 (06): : 688 - 700
  • [25] Oxidized lipids as mediators of coronary heart disease
    Navab, M
    Hama, SY
    Ready, ST
    Ng, CJ
    Van Lenten, BJ
    Laks, H
    Fogelman, AM
    CURRENT OPINION IN LIPIDOLOGY, 2002, 13 (04) : 363 - 372
  • [26] Next Steps in Primary Prevention of Coronary Heart Disease Rationale for and Design of the ECAD Trial
    Domanski, Michael J.
    Fuster, Valentin
    Diaz-Mitoma, Francisco
    Grundy, Scott
    Lloyd-Jones, Donald
    Mamdani, Muhammad
    Roberts, Robin
    Thorpe, Kevin
    Hall, Judith
    Udell, Jacob A.
    Farkouh, Michael E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (16) : 1828 - 1836
  • [27] Update of antibiotic trials for secondary prevention of coronary heart disease
    Anderson, J. L.
    Muhlestein, J. B.
    FUTURE CARDIOLOGY, 2005, 1 (02) : 225 - 234
  • [28] Prevention of coronary heart disease and the national cholesterol education program
    Kuller, LH
    CIRCULATION, 2006, 113 (05) : 598 - 600
  • [29] Coronary heart disease in young women: problems of diagnostics and prevention
    Lebedeva, A. Yu.
    Klykov, L. L.
    Zaitseva, V. V.
    RUSSIAN JOURNAL OF CARDIOLOGY, 2011, (06): : 90 - 97
  • [30] Reversing social disadvantage in secondary prevention of coronary heart disease
    Jelinek, Michael V.
    Santamaria, John D.
    Best, James D.
    Thompson, David R.
    Tonkin, Andrew M.
    Vale, Margarite J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 171 (03) : 346 - 350